Form 4: Celldex Therapeutics SVP and CFO Martin Samuel Bates Reports Stock Transactions

Martin Samuel Bates, SVP and CFO of Celldex Therapeutics, reports the exercise of stock options and subsequent sale of shares on June 14, 2024.

Summary

• On June 14, 2024, Martin Samuel Bates, SVP and CFO of Celldex Therapeutics, exercised incentive stock options to acquire 3,201 shares at $9.0165 and 16,968 shares at $10.38.
• Following the exercise of these options, Mr. Bates sold 17,172 shares at a weighted average price of $35.4248, with individual sales ranging from $34.89 to $35.76 per share.
• After these transactions, Mr. Bates directly owns 28,125 shares of Celldex Therapeutics common stock.
• Mr. Bates also holds incentive stock options for 63,632 shares.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings to gauge management's sentiment about the company's prospects, although individual transactions can be driven by various personal financial considerations.

Comparison to Industry Standards

• Insider trading activity is a common occurrence in publicly listed companies, and the reporting requirements are standardized by the SEC.
• Comparing the volume and frequency of insider transactions at Celldex to similar biotech companies like Amgen or Regeneron could provide insights into the overall sentiment surrounding the stock.
• However, without additional context, it's difficult to assess whether these transactions are indicative of a broader trend or simply reflect individual financial planning.

Stakeholder Impact

• The sale of shares by a high-ranking executive could be perceived negatively by some shareholders, potentially leading to a slight decrease in stock price.
• However, the impact is likely to be minimal given the relatively small number of shares sold compared to the company's overall market capitalization.

Key Dates